Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- ACCEL Lite: Primary Results From the SOUL Randomized TrialIn this episode, Drs. Deepak L. Bhatt and Darren K. McGuire explore how the SOUL trial further strengthens the favorable risk-benefit profile of oral semaglutide for patients with T2DM and coexisting ASCVD and/or CKD, highlighting its potential to reshape CV risk management in this high-risk population.
- CVD Risk in Cancer Survivors Varies By Cancer Type and TreatmentThe long-term risk of cardiovascular disease (CVD) among cancer survivors can vary significantly based on cancer type and treatment, according to a nationwide cohort study published June 17 in JACC: CardioOncology.
- Contraceptive Planning For Women With and Without Cardiovascular DiseaseThis article highlights the critical role of preconception counseling and effective contraceptive planning for women of reproductive age with cardiovascular disease (CVD).
- Wildfire Smoke-Related Fine Particulate Matter Linked to Higher Risk of HFLong-term exposure to wildfire smoke-related fine particulate matter (defined as PM2.5) was linked to a higher risk of heart failure (HF) in older adults compared with non-wildfire smoke PM2.5, according to a new study published in JACC.
- ACC CardiaCast: Moving the Needle: Clinical Strategies Focusing on Controlling LDL-CIn this episode of CardiaCast, Drs. Erin Michos and Joseph Saseen discuss the underuse of lipid-lowering therapies in patients with cardiovascular risk, despite strong evidence and updated guidelines.